Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (19543)	4/24/1998 11:42:00 AM
From: Henry Niman	Respond to of 32384

Jo, The most obvious application for topical use of Panretin would be skin disease since a subset of the receptors that it targets (RARs) are also targeted by Retin-A, Renova, and Accutane. However, LGND seems to be exploring oral applications (of Panretin and Targretin) for psoriasis. As far as off label use is concerned, I think that LGND expects significant revenues for the oral formulas used to treat various advanced cancers. I'm taking off for more soccer this weekend. Good luck with the upcoming "Wait till Monday" and "who's dumping now" posts (the 50K block earlier this morning did look like a sell - it wasn't paired with another large block and the bid subsequently fell).